

# Anthony Iafrate

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6170411/publications.pdf>

Version: 2024-02-01

139  
papers

18,815  
citations

27035

58  
h-index

17373

126  
g-index

144  
all docs

144  
docs citations

144  
times ranked

32937  
citing authors

#	ARTICLE	IF	CITATIONS
1	t(4;12)(q12;p13) ETV6-rearranged AML without eosinophilia does not involve PDGFRA: relevance for imatinib insensitivity. <i>Blood Advances</i> , 2022, 6, 818-827.	2.5	5
2	Immunogenicity and Reactogenicity of SARS-CoV-2 Vaccines in Patients With Cancer: The CANVAX Cohort Study. <i>Journal of Clinical Oncology</i> , 2022, 40, 12-23.	0.8	75
3	Cell-Free HPV DNA Provides an Accurate and Rapid Diagnosis of HPV-Associated Head and Neck Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 719-727.	3.2	46
4	Neutralization breadth of SARS-CoV-2 viral variants following primary series and booster SARS-CoV-2 vaccines in patients with cancer. <i>Cancer Cell</i> , 2022, 40, 103-108.e2.	7.7	30
5	mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant. <i>Cell</i> , 2022, 185, 457-466.e4.	13.5	881
6	T cell reactivity to the SARS-CoV-2 Omicron variant is preserved in most but not all individuals. <i>Cell</i> , 2022, 185, 1041-1051.e6.	13.5	187
7	Cell-free human papillomavirus DNA kinetics after surgery for human papillomavirus-associated oropharyngeal cancer. <i>Cancer</i> , 2022, 128, 2193-2204.	2.0	35
8	Comparative Immunogenicity and Effectiveness of mRNA-1273, BNT162b2, and Ad26.COVS COVID-19 Vaccines. <i>Journal of Infectious Diseases</i> , 2022, 225, 1141-1150.	1.9	102
9	Abstract P3-23-02: Immunogenicity of SARS-CoV-2 vaccines in patients with breast cancer receiving CDK 4/6 inhibitors. <i>Cancer Research</i> , 2022, 82, P3-23-02-P3-23-02.	0.4	0
10	Detection of EWSR1 fusions in CCOC by targeted RNA-seq. <i>Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology</i> , 2022, 134, 240-244.	0.2	7
11	Repertoires of SARS-CoV-2 epitopes targeted by antibodies vary according to severity of COVID-19. <i>Virulence</i> , 2022, 13, 890-902.	1.8	8
12	Simultaneous Identification of Cell of Origin, Translocations, and Hotspot Mutations in Diffuse Large B-Cell Lymphoma Using a Single RNA-Sequencing Assay. <i>American Journal of Clinical Pathology</i> , 2021, 155, 748-754.	0.4	9
13	COVID-19-neutralizing antibodies predict disease severity and survival. <i>Cell</i> , 2021, 184, 476-488.e11.	13.5	586
14	Tumor Tissue-versus Plasma-based Genotyping for Selection of Matched Therapy and Impact on Clinical Outcomes in Patients with Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 3404-3413.	3.2	10
15	Palbociclib demonstrates intracranial activity in progressive brain metastases harboring cyclin-dependent kinase pathway alterations. <i>Nature Cancer</i> , 2021, 2, 498-502.	5.7	26
16	Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity. <i>Cell</i> , 2021, 184, 2372-2383.e9.	13.5	1,166
17	Landscape of GATA3 mutations identified from circulating tumor DNA clinical testing and their impact on disease outcomes in estrogen receptor-positive (ER+) metastatic breast cancers treated with endocrine therapies.. <i>Journal of Clinical Oncology</i> , 2021, 39, 1065-1065.	0.8	1
18	Nanopore Flongle Sequencing as a Rapid, Single-Specimen Clinical Test for Fusion Detection. <i>Journal of Molecular Diagnostics</i> , 2021, 23, 630-636.	1.2	11

#	ARTICLE	IF	CITATIONS
19	Mosaicism for Receptor Tyrosine Kinase Activation in a Glioblastoma Involving Both PDGFRA Amplification and NTRK2 Fusion. <i>Oncologist</i> , 2021, 26, 919-924.	1.9	6
20	Structure-guided T&Acell vaccine design for SARS-CoV-2 variants and sarbecoviruses. <i>Cell</i> , 2021, 184, 4401-4413.e10.	13.5	65
21	Remote Fingerstick Blood Collection for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibody Testing. <i>Archives of Pathology and Laboratory Medicine</i> , 2021, 145, 415-418.	1.2	10
22	Defining genome-wide CRISPR&Aacute;Cas genome-editing nuclease activity with GUIDE-seq. <i>Nature Protocols</i> , 2021, 16, 5592-5615.	5.5	27
23	The Molecular Analysis for Therapy Choice (NCI-MATCH) Trial: Lessons for Genomic Trial Design. <i>Journal of the National Cancer Institute</i> , 2020, 112, 1021-1029.	3.0	138
24	Rising Circulating Tumor DNA As a Molecular Biomarker of Early Disease Progression in Metastatic Breast Cancer. <i>JCO Precision Oncology</i> , 2020, 4, 1246-1262.	1.5	16
25	Persistence and decay of human antibody responses to the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 patients. <i>Science Immunology</i> , 2020, 5, .	5.6	561
26	Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH). <i>Journal of Clinical Oncology</i> , 2020, 38, 3883-3894.	0.8	168
27	Cytomorphologic characteristics of next-generation sequencing&Aacute;positive bile duct brushing specimens. <i>Journal of the American Society of Cytopathology</i> , 2020, 9, 520-527.	0.2	4
28	High Seroprevalence of Anti-SARS-CoV-2 Antibodies in Chelsea, Massachusetts. <i>Journal of Infectious Diseases</i> , 2020, 222, 1955-1959.	1.9	72
29	Identification of Somatic Acquired <i>BRCA1/2</i> Mutations by cfDNA Analysis in Patients with Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 4852-4862.	3.2	12
30	Genomic characterization of human brain metastases identifies drivers of metastatic lung adenocarcinoma. <i>Nature Genetics</i> , 2020, 52, 371-377.	9.4	177
31	A cryptic imatinib-sensitive G3BP1-PDGFRB rearrangement in a myeloid neoplasm with eosinophilia. <i>Blood Advances</i> , 2020, 4, 445-448.	2.5	11
32	Serial ctDNA Monitoring to Predict Response to Systemic Therapy in Metastatic Gastrointestinal Cancers. <i>Clinical Cancer Research</i> , 2020, 26, 1877-1885.	3.2	67
33	Alliance A071401: Phase II trial of FAK inhibition in meningiomas with somatic NF2 mutations.. <i>Journal of Clinical Oncology</i> , 2020, 38, 2502-2502.	0.8	17
34	Alliance A071701: Genomically guided treatment trial in brain metastases.. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS2573-TPS2573.	0.8	4
35	Blood-based monitoring identifies acquired and targetable driver HER2 mutations in endocrine-resistant metastatic breast cancer. <i>Npj Precision Oncology</i> , 2019, 3, 18.	2.3	25
36	Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers. <i>Nature Medicine</i> , 2019, 25, 1415-1421.	15.2	359

#	ARTICLE	IF	CITATIONS
37	Molecular characteristics of poorly differentiated chordoma. <i>Genes Chromosomes and Cancer</i> , 2019, 58, 804-808.	1.5	23
38	Polysomy is associated with poor outcome in 1p/19q codeleted oligodendroglial tumors. <i>Neuro-Oncology</i> , 2019, 21, 1164-1174.	0.6	12
39	TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion-Positive Intrahepatic Cholangiocarcinoma. <i>Cancer Discovery</i> , 2019, 9, 1064-1079.	7.7	254
40	Clinical Validation of a Cell-Free DNA Gene Panel. <i>Journal of Molecular Diagnostics</i> , 2019, 21, 632-645.	1.2	15
41	Expediting Comprehensive Molecular Analysis to Optimize Initial Treatment of Lung Cancer Patients With Minimal Smoking History. <i>Journal of Thoracic Oncology</i> , 2019, 14, 835-843.	0.5	9
42	Highly Multiplexed Fluorescence in Situ Hybridization for in Situ Genomics. <i>Journal of Molecular Diagnostics</i> , 2019, 21, 390-407.	1.2	15
43	PI3K/AKT/mTOR Pathway Alterations Promote Malignant Progression and Xenograft Formation in Oligodendroglial Tumors. <i>Clinical Cancer Research</i> , 2019, 25, 4375-4387.	3.2	26
44	A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring <i>FGFR</i> Gene Alterations. <i>Clinical Cancer Research</i> , 2019, 25, 2699-2707.	3.2	98
45	Enrichment of <i>HER2</i> Amplification in Brain Metastases from Primary Gastrointestinal Malignancies. <i>Oncologist</i> , 2019, 24, 193-201.	1.9	16
46	Functional and topographic effects on DNA methylation in IDH1/2 mutant cancers. <i>Scientific Reports</i> , 2019, 9, 16830.	1.6	29
47	GENE-63. GENOMIC CHARACTERIZATION OF HUMAN BRAIN METASTASES IDENTIFIES NOVEL DRIVERS OF LUNG ADENOCARCINOMA PROGRESSION. <i>Neuro-Oncology</i> , 2019, 21, vi111-vi111.	0.6	1
48	CMET-33. PHASE II STUDY OF PALBOCICLIB IN BRAIN METASTASES HARBORING CDK PATHWAY ALTERATIONS. <i>Neuro-Oncology</i> , 2019, 21, vi58-vi59.	0.6	0
49	Impact of BRAF Mutation Class on Disease Characteristics and Clinical Outcomes in BRAF-mutant Lung Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 158-165.	3.2	81
50	Isocitrate dehydrogenase 1 and 2 mutations, 2-hydroxyglutarate levels, and response to standard chemotherapy for patients with newly diagnosed acute myeloid leukemia. <i>Cancer</i> , 2019, 125, 541-549.	2.0	23
51	Genetically distinct glioma stem-like cell xenografts established from paired glioblastoma samples harvested before and after molecularly targeted therapy. <i>Scientific Reports</i> , 2019, 9, 139.	1.6	9
52	Differential expression of PD-L1 and IDO1 in association with the immune microenvironment in resected lung adenocarcinomas. <i>Modern Pathology</i> , 2019, 32, 511-523.	2.9	33
53	Proficiency Testing of Standardized Samples Shows Very High Interlaboratory Agreement for Clinical Next-Generation Sequencing-Based Oncology Assays. <i>Archives of Pathology and Laboratory Medicine</i> , 2019, 143, 463-471.	1.2	32
54	Financially effective test algorithm to identify an aggressive, EGFR-amplified variant of IDH-wildtype, lower-grade diffuse glioma. <i>Neuro-Oncology</i> , 2019, 21, 596-605.	0.6	25

#	ARTICLE	IF	CITATIONS
55	A Nanopore Sequencing-Based Assay for Rapid Detection of Gene Fusions. <i>Journal of Molecular Diagnostics</i> , 2019, 21, 58-69.	1.2	34
56	Design and development of the molecular analysis for Therapy Choice (NCI-MATCH) Designated Laboratory Network.. <i>Journal of Clinical Oncology</i> , 2019, 37, 3016-3016.	0.8	2
57	An artificial intelligence approach to variant calling of ALK resistance mutations.. <i>Journal of Clinical Oncology</i> , 2019, 37, 3079-3079.	0.8	0
58	Pharmacodynamics of mutant-IDH1 inhibitors in glioma patients probed by in vivo 3D MRS imaging of 2-hydroxyglutarate. <i>Nature Communications</i> , 2018, 9, 1474.	5.8	106
59	Convergent Therapeutic Strategies to Overcome the Heterogeneity of Acquired Resistance in BRAF <sup>V600E</sup> Colorectal Cancer. <i>Cancer Discovery</i> , 2018, 8, 417-427.	7.7	61
60	MET Amplification in Esophageal Squamous Carcinoma. <i>International Journal of Surgical Pathology</i> , 2018, 26, 731-732.	0.4	2
61	NTRK Fusions Define a Novel Uterine Sarcoma Subtype With Features of Fibrosarcoma. <i>American Journal of Surgical Pathology</i> , 2018, 42, 791-798.	2.1	182
62	Expressed Gene Fusions as Frequent Drivers of Poor Outcomes in Hormone Receptor-Positive Breast Cancer. <i>Cancer Discovery</i> , 2018, 8, 336-353.	7.7	32
63	Clinicopathologic Features of Non-Small-Cell Lung Cancer Harboring an NTRK Gene Fusion. <i>JCO Precision Oncology</i> , 2018, 2018, 1-12.	1.5	112
64	Tracking the Evolution of Resistance to ALK Tyrosine Kinase Inhibitors Through Longitudinal Analysis of Circulating Tumor DNA. <i>JCO Precision Oncology</i> , 2018, 2018, 1-14.	1.5	86
65	Artificial Intelligence Approach for Variant Reporting. <i>JCO Clinical Cancer Informatics</i> , 2018, 2, 1-13.	1.0	13
66	Clinical Utility of Rapid EGFR Genotyping in Advanced Lung Cancer. <i>JCO Precision Oncology</i> , 2018, 2018, 1-13.	1.5	17
67	EPID-11. PROGRESSION OF IDH MUTANT GLIOMA AFTER FIRST RECURRENCE: DEVELOPMENT OF A FEASIBLE CLINICAL TRIAL ENDPOINT IN THE RECURRENT SETTING. <i>Neuro-Oncology</i> , 2018, 20, vi82-vi82.	0.6	0
68	Landscape of Acquired Resistance to Osimertinib in EGFR-Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired RET Fusion. <i>Cancer Discovery</i> , 2018, 8, 1529-1539.	7.7	342
69	TERT promoter wild-type glioblastomas show distinct clinical features and frequent PI3K pathway mutations. <i>Acta Neuropathologica Communications</i> , 2018, 6, 106.	2.4	18
70	Primary tumor sidedness is an independent prognostic marker for survival in metastatic colorectal cancer: Results from a large retrospective cohort with mutational analysis. <i>Cancer Medicine</i> , 2018, 7, 2934-2942.	1.3	21
71	Genotype-targeted local therapy of glioma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E8388-E8394.	3.3	40
72	Widespread Chromosomal Losses and Mitochondrial DNA Alterations as Genetic Drivers in Heritable Cell Carcinoma. <i>Cancer Cell</i> , 2018, 34, 242-255.e5.	7.7	185

#	ARTICLE	IF	CITATIONS
73	DMD genomic deletions characterize a subset of progressive/higher-grade meningiomas with poor outcome. <i>Acta Neuropathologica</i> , 2018, 136, 779-792.	3.9	66
74	Implementing the DICOM Standard for Digital Pathology. <i>Journal of Pathology Informatics</i> , 2018, 9, 37.	0.8	93
75	Comparison of tissue genotyping (TC) vs circulating tumor DNA (ctDNA) for selection of matched therapy and impact on clinical outcomes among patients with metastatic breast cancer (MBC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 1020-1020.	0.8	10
76	BRAF-mutant non-small cell lung cancer (NSCLC): Patient (pt) characteristics and outcomes by class of mutation.. <i>Journal of Clinical Oncology</i> , 2018, 36, 9045-9045.	0.8	0
77	Analytical Validation of the Next-Generation Sequencing Assay for a Nationwide Signal-Finding Clinical Trial. <i>Journal of Molecular Diagnostics</i> , 2017, 19, 313-327.	1.2	115
78	Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	3.0	82
79	The Alkylating Chemotherapeutic Temozolomide Induces Metabolic Stress in <i>IDH1</i> -Mutant Cancers and Potentiates NAD <sup>+</sup> Depletion-Mediated Cytotoxicity. <i>Cancer Research</i> , 2017, 77, 4102-4115.	0.4	74
80	Polyclonal Secondary <i>FGFR2</i> Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with <i>FGFR2</i> Fusion-Positive Cholangiocarcinoma. <i>Cancer Discovery</i> , 2017, 7, 252-263.	7.7	384
81	Clinical and radiographic response following targeting of <i>BCAN-NTRK1</i> fusion in glioneuronal tumor. <i>Npj Precision Oncology</i> , 2017, 1, 5.	2.3	49
82	Blockade of transforming growth factor- $\beta$ signaling enhances oncolytic herpes simplex virus efficacy in patient-derived recurrent glioblastoma models. <i>International Journal of Cancer</i> , 2017, 141, 2348-2358.	2.3	33
83	<i>GNAS</i> mutations in primary mucinous and non-mucinous lung adenocarcinomas. <i>Modern Pathology</i> , 2017, 30, 1720-1727.	2.9	33
84	Recurrent and functional regulatory mutations in breast cancer. <i>Nature</i> , 2017, 547, 55-60.	13.7	269
85	Next-generation sequencing adds value to the preoperative diagnosis of pancreatic cysts. <i>Cancer Cytopathology</i> , 2017, 125, 41-47.	1.4	86
86	Patterns of Metastatic Spread and Mechanisms of Resistance to Crizotinib in <i>ROS1</i> -Positive Non-Small-Cell Lung Cancer. <i>JCO Precision Oncology</i> , 2017, 2017, 1-13.	1.5	158
87	Tumor genomics and response to CDK 4/6 inhibitors for patients with hormone receptor-positive (HR+) metastatic breast cancer (MBC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 1046-1046.	0.8	4
88	MPTH-34. THE PROGNOSTIC VALUE OF POLYSOMY IN OLIGODENDROGLIAL TUMORS. <i>Neuro-Oncology</i> , 2016, 18, vi113-vi113.	0.6	0
89	Pan-cancer analysis of copy number changes in programmed death-ligand 1 (PD-L1, CD274) associations with gene expression, mutational load, and survival. <i>Genes Chromosomes and Cancer</i> , 2016, 55, 626-639.	1.5	80
90	<i>IDH2</i> Mutations Define a Unique Subtype of Breast Cancer with Altered Nuclear Polarity. <i>Cancer Research</i> , 2016, 76, 7118-7129.	0.4	99

#	ARTICLE	IF	CITATIONS
91	<i>MET</i> Exon 14 Skipping in Non-Small Cell Lung Cancer. <i>Oncologist</i> , 2016, 21, 481-486.	1.9	94
92	Myc-Driven Glycolysis Is a Therapeutic Target in Glioblastoma. <i>Clinical Cancer Research</i> , 2016, 22, 4452-4465.	3.2	112
93	Acquired Resistance to Crizotinib in NSCLC with <i>MET</i> Exon 14 Skipping. <i>Journal of Thoracic Oncology</i> , 2016, 11, 1242-1245.	0.5	140
94	Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in <i>ALK</i> -Rearranged Lung Cancer. <i>Cancer Discovery</i> , 2016, 6, 1118-1133.	7.7	919
95	Next-Generation Sequencing and Fluorescence in Situ Hybridization Have Comparable Performance Characteristics in the Analysis of Pancreaticobiliary Brushings for Malignancy. <i>Journal of Molecular Diagnostics</i> , 2016, 18, 124-130.	1.2	79
96	Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer. <i>Cancer Discovery</i> , 2016, 6, 147-153.	7.7	338
97	P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer. <i>EBioMedicine</i> , 2016, 3, 54-66.	2.7	123
98	Resensitization to Crizotinib by the Lorlatinib <i>ALK</i> Resistance Mutation L1198F. <i>New England Journal of Medicine</i> , 2016, 374, 54-61.	13.9	433
99	Impact of next-generation sequencing on the clinical diagnosis of pancreatic cysts. <i>Gastrointestinal Endoscopy</i> , 2016, 83, 140-148.	0.5	119
100	Treatment Response Assessment in IDH-Mutant Glioma Patients by Noninvasive 3D Functional Spectroscopic Mapping of 2-Hydroxyglutarate. <i>Clinical Cancer Research</i> , 2016, 22, 1632-1641.	3.2	127
101	ALK FISH positivity and crizotinib efficacy in patients (pts) with non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 9062-9062.	0.8	0
102	Novel EPHB4 Receptor Tyrosine Kinase Mutations and Kinomic Pathway Analysis in Lung Cancer. <i>Scientific Reports</i> , 2015, 5, 10641.	1.6	17
103	HCP-12IMPROVING THE EFFICIENCY OF MOLECULAR TESTING FOR EXPEDITED BRAIN TUMOR PATIENT MANAGEMENT AND CLINICAL TRIAL ENROLLMENT. <i>Neuro-Oncology</i> , 2015, 17, v103.4-v104.	0.6	0
104	Extreme Vulnerability of IDH1 Mutant Cancers to NAD <sup>+</sup> Depletion. <i>Cancer Cell</i> , 2015, 28, 773-784.	7.7	327
105	CCR 20th Anniversary Commentary: Molecular Pathology of ALK-Rearranged Lung Tumors. <i>Clinical Cancer Research</i> , 2015, 21, 5185-5187.	3.2	1
106	MYC Analysis by Fluorescent In Situ Hybridization and Immunohistochemistry in Primary Adrenal Angiosarcoma (PAA): a Series of Four Cases. <i>Endocrine Pathology</i> , 2015, 26, 334-341.	5.2	10
107	Impact of NRAS Mutations for Patients with Advanced Melanoma Treated with Immune Therapies. <i>Cancer Immunology Research</i> , 2015, 3, 288-295.	1.6	145
108	Heterogeneity Underlies the Emergence of <i>EGFR</i> T790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor. <i>Cancer Discovery</i> , 2015, 5, 713-722.	7.7	429



#	ARTICLE	IF	CITATIONS
109	Inconsistency and features of single nucleotide variants detected in whole exome sequencing versus transcriptome sequencing: A case study in lung cancer. <i>Methods</i> , 2015, 83, 118-127.	1.9	33
110	Prognosis and Clinicopathologic Features of Patients With Advanced Stage Isocitrate Dehydrogenase (IDH) Mutant and IDH Wild-Type Intrahepatic Cholangiocarcinoma. <i>Oncologist</i> , 2015, 20, 1019-1027.	1.9	112
111	Detection of Dual IDH1 and IDH2 Mutations by Targeted Next-Generation Sequencing in Acute Myeloid Leukemia and Myelodysplastic Syndromes. <i>Journal of Molecular Diagnostics</i> , 2015, 17, 661-668.	1.2	31
112	Variant Profiling of Candidate Genes in Pancreatic Ductal Adenocarcinoma. <i>Clinical Chemistry</i> , 2015, 61, 1408-1416.	1.5	21
113	GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases. <i>Nature Biotechnology</i> , 2015, 33, 187-197.	9.4	1,757
114	High p53 protein expression in therapy-related myeloid neoplasms is associated with adverse karyotype and poor outcome. <i>Modern Pathology</i> , 2015, 28, 552-563.	2.9	42
115	Clinical implementation of anchored multiplex PCR with targeted next-generation sequencing for detection of ALK, ROS1, RET and NTRK1 fusions in non-small cell lung carcinoma.. <i>Journal of Clinical Oncology</i> , 2015, 33, 8095-8095.	0.8	1
116	Clinical characteristics and treatment outcomes of patients with metastatic, MET-amplified esophagogastric cancers.. <i>Journal of Clinical Oncology</i> , 2015, 33, 4043-4043.	0.8	0
117	Clinical Utility of a Blood-Based BRAFV600E Mutation Assay in Melanoma. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 3210-3218.	1.9	21
118	Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 1998.	3.8	1,386
119	Targetable Signaling Pathway Mutations Are Associated with Malignant Phenotype in IDH-Mutant Gliomas. <i>Clinical Cancer Research</i> , 2014, 20, 2898-2909.	3.2	146
120	Anchored multiplex PCR for targeted next-generation sequencing. <i>Nature Medicine</i> , 2014, 20, 1479-1484.	15.2	705
121	Patient-derived models of acquired resistance can identify effective drug combinations for cancer. <i>Science</i> , 2014, 346, 1480-1486.	6.0	635
122	Two Novel ALK Mutations Mediate Acquired Resistance to the Next-Generation ALK Inhibitor Alectinib. <i>Clinical Cancer Research</i> , 2014, 20, 5686-5696.	3.2	261
123	Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility. <i>Science</i> , 2014, 345, 216-220.	6.0	808
124	Genome Editing: A Tool For Research and Therapy: Towards a functional understanding of variants for molecular diagnostics using genome editing. <i>Nature Medicine</i> , 2014, 20, 1103-1104.	15.2	14
125	High Lung Shunt Fraction in Colorectal Liver Tumors Is Associated with Distant Metastasis and Decreased Survival. <i>Journal of Vascular and Interventional Radiology</i> , 2014, 25, 1604-1608.	0.2	25
126	Brain Tumor Cells in Circulation Are Enriched for Mesenchymal Gene Expression. <i>Cancer Discovery</i> , 2014, 4, 1299-1309.	7.7	207



#	ARTICLE	IF	CITATIONS
127	Effect of molecular genotyping to predict outcomes in patients with metastatic pancreatic cancer.. Journal of Clinical Oncology, 2014, 32, 4128-4128.	0.8	3
128	Efficacy and safety of crizotinib in patients with advanced <i>c-MET</i> -amplified non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2014, 32, 8001-8001.	0.8	176
129	Clinical grade "SNaPshot" genetic mutation profiling in multiple myeloma.. Journal of Clinical Oncology, 2014, 32, e19571-e19571.	0.8	0
130	Targetable signaling pathway mutations and progression of <i>IDH</i> -mutant glioma.. Journal of Clinical Oncology, 2014, 32, 2061-2061.	0.8	0
131	Update on Glioma Treatments in the United States. Japanese Journal of Neurosurgery, 2013, 22, 590-596.	0.0	0
132	Reply to T. Komiya et al. Journal of Clinical Oncology, 2012, 30, 3426-3426.	0.8	1
133	FGFR1 Amplification in Squamous Cell Carcinoma of The Lung. Journal of Thoracic Oncology, 2012, 7, 1775-1780.	0.5	197
134	Clinical activity of crizotinib in advanced non-small cell lung cancer (NSCLC) harboring ROS1 gene rearrangement.. Journal of Clinical Oncology, 2012, 30, 7508-7508.	0.8	65
135	ALK and MET genes in advanced lung adenocarcinomas: The Lung Cancer Mutation Consortium experience.. Journal of Clinical Oncology, 2012, 30, 7589-7589.	0.8	7
136	A phase II trial of dasatinib in patients with unresectable locally advanced or stage IV mucosal, acral, and solar melanomas: An Eastern Cooperative Oncology Group study (E2607).. Journal of Clinical Oncology, 2012, 30, 8522-8522.	0.8	2
137	Prospective evaluation of serial 2-hydroxyglutarate in acute myeloid leukemia (AML) to determine response to therapy and predict relapse.. Journal of Clinical Oncology, 2012, 30, 6606-6606.	0.8	0
138	MGMT for pt mgmt: Is Methylguanine-DNA Methyltransferase Testing Ready for Patient Management?. Journal of Molecular Diagnostics, 2008, 10, 308-310.	1.2	9
139	An Analysis of Reference Laboratory Testing in a Large Urban Academic Medical Center: The Impact of New Molecular Diagnostic Technologies. Laboratory Medicine, 2007, 38, 472-475.	0.8	3